Researchers at GSK plc have developed cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) consisting of a cell-surface protein targeting moiety (particularly, folate receptors) covalently linked to a moiety targeting an exogenous antibody (such as anti-cotinine antibody) through a linker.
Eisai R&D Management Co. Ltd., National Institutes for Quantum and Radiological Science and Technology (QST), Ono Pharmaceutical Co. Ltd. and Takeda Pharmaceutical Co. Ltd. have patented new radiolabeled compounds targeting α-synuclein (α-Syn, SNCA) and acting as optical imaging agents for the diagnosis of Lewy body dementia (DLB), multiple system atrophy and Parkinson’s disease.
Di-cyclopropyl based interleukin-17A (IL-17A) production inhibitors have been reported in a Dice Alpha Inc. patent as potentially useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.
The U.S. FTC put brand drug companies on notice Sept. 14 when the commissioners unanimously voted, 3-0, to issue a policy statement recognizing that improperly listed patents in the FDA’s Orange Book “may constitute an unfair method of competition.”
Research at Medshine Discovery Inc. has led to the development of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors potentially useful for the treatment of SARS-CoV-2 infection (COVID-19).
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of chronic obstructive pulmonary disease, fibrosis, psoriasis, erectile dysfunction, multiple sclerosis, heart failure, overactive bladder and neuropathic pain, among others.
Researchers at the University of Bonn and Westfälische Wilhelms-Universiteit Münster have prepared labeled compounds acting as 5’-nucleotidase (CD73) inhibitors.
Sanofi SA has identified thienopyrrolotriazine compounds reported to be useful for the treatment of multiple system atrophy, frontotemporal dementia, multiple sclerosis, amyotrophic lateral sclerosis, brain injury, Alzheimer’s and Parkinson’s disease.
Amgen Inc. has patented new quinazoline compounds acting as GTPase KRAS (G12D mutant) inhibitors and thus reported to be useful for the treatment of cancer.
Arizona State University (ASU) reported the receipt of a patent for a device with colorimetric sensors for measuring excreted ketones in a body fluid. Additional sensors may be incorporated to measure flow rate of the body fluid, barometric pressure, humidity, and chemicals such as oxygen and carbon dioxide present in the fluid, and a system to measure metabolic rate and respiratory quotient via oxygen consumption rate and carbon dioxide production rate.
RSS
